Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.

Weerts EM, Wand GS, Kuwabara H, Xu X, Frost JJ, Wong DF, McCaul ME.

Addict Biol. 2014 Jul;19(4):733-42. doi: 10.1111/adb.12022. Epub 2012 Dec 18.

2.

Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects.

Weerts EM, Wand GS, Kuwabara H, Munro CA, Dannals RF, Hilton J, Frost JJ, McCaul ME.

Alcohol Clin Exp Res. 2011 Dec;35(12):2162-73. doi: 10.1111/j.1530-0277.2011.01565.x. Epub 2011 Jun 20.

3.

Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects.

Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, McCaul ME.

Neuropsychopharmacology. 2008 Feb;33(3):653-65. Epub 2007 May 9.

4.

Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil.

Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G, Dohmen BM, Braus DF, Schumann G, Machulla HJ, Bares R, Mann K.

Arch Gen Psychiatry. 2005 Jan;62(1):57-64. Erratum in: Arch Gen Psychiatry. 2005 Sep;62(9):983. Braus, Dieter H [corrected to Braus, Dieter F].

PMID:
15630073
5.

Regional brain activity correlates of nicotine dependence.

Rose JE, Behm FM, Salley AN, Bates JE, Coleman RE, Hawk TC, Turkington TG.

Neuropsychopharmacology. 2007 Dec;32(12):2441-52. Epub 2007 Mar 14.

6.

Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans.

Scott DJ, Domino EF, Heitzeg MM, Koeppe RA, Ni L, Guthrie S, Zubieta JK.

Neuropsychopharmacology. 2007 Feb;32(2):450-7. Epub 2006 Nov 8.

7.

Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence.

Bencherif B, Wand GS, McCaul ME, Kim YK, Ilgin N, Dannals RF, Frost JJ.

Biol Psychiatry. 2004 Feb 1;55(3):255-62.

PMID:
14744466
8.

The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjects.

Wand GS, Weerts EM, Kuwabara H, Wong DF, Xu X, McCaul ME.

Addict Biol. 2013 Jan;18(1):181-92. doi: 10.1111/j.1369-1600.2011.00430.x. Epub 2012 Jan 20.

9.

Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse.

Fehr C, Yakushev I, Hohmann N, Buchholz HG, Landvogt C, Deckers H, Eberhardt A, Kläger M, Smolka MN, Scheurich A, Dielentheis T, Schmidt LG, Rösch F, Bartenstein P, Gründer G, Schreckenberger M.

Am J Psychiatry. 2008 Apr;165(4):507-14. doi: 10.1176/appi.ajp.2007.07020352. Epub 2008 Mar 3.

PMID:
18316420
10.

Nicotine-specific and non-specific effects of cigarette smoking on endogenous opioid mechanisms.

Nuechterlein EB, Ni L, Domino EF, Zubieta JK.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Aug 1;69:69-77. doi: 10.1016/j.pnpbp.2016.04.006. Epub 2016 Apr 17.

PMID:
27095017
11.

Naltrexone alteration of acute smoking response in nicotine-dependent subjects.

King AC, Meyer PJ.

Pharmacol Biochem Behav. 2000 Jul;66(3):563-72.

PMID:
10899371
12.

Smoking history, nicotine dependence, and changes in craving and mood during short-term smoking abstinence in alcohol dependent vs. control smokers.

Heffner JL, Mingione C, Blom TJ, Anthenelli RM.

Addict Behav. 2011 Mar;36(3):244-7. doi: 10.1016/j.addbeh.2010.10.008. Epub 2010 Oct 28.

13.

Regional brain [(11)C]carfentanil binding following tobacco smoking.

Domino EF, Hirasawa-Fujita M, Ni L, Guthrie SK, Zubieta JK.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jun 3;59:100-4. doi: 10.1016/j.pnpbp.2015.01.007. Epub 2015 Jan 15.

14.

Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study.

Spreckelmeyer KN, Paulzen M, Raptis M, Baltus T, Schaffrath S, Van Waesberghe J, Zalewski MM, Rösch F, Vernaleken I, Schäfer WM, Gründer G.

Biol Psychiatry. 2011 Oct 15;70(8):770-6. doi: 10.1016/j.biopsych.2011.05.035. Epub 2011 Jul 29.

PMID:
21802658
15.

Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study.

Williams TM, Davies SJ, Taylor LG, Daglish MR, Hammers A, Brooks DJ, Nutt DJ, Lingford-Hughes A.

Eur Neuropsychopharmacol. 2009 Oct;19(10):740-8. doi: 10.1016/j.euroneuro.2009.06.007.

PMID:
19595579
16.

Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers.

Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C, Blendy JA, Logan J, Zubieta JK, Lerman C.

Proc Natl Acad Sci U S A. 2011 May 31;108(22):9268-73. doi: 10.1073/pnas.1018699108. Epub 2011 May 16.

17.

Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women.

King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, deWit H, Matthews AK, Stachoviak RJ.

J Clin Psychopharmacol. 2012 Oct;32(5):630-6. doi: 10.1097/JCP.0b013e3182676956.

18.

The relationship between naloxone-induced cortisol and mu opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects.

Wand GS, Weerts EM, Kuwabara H, Wong DF, Xu X, McCaul ME.

Alcohol. 2012 Sep;46(6):511-7. doi: 10.1016/j.alcohol.2012.04.006. Epub 2012 Jun 18.

19.
20.

Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.

Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH; VA Cooperative Study #425 Study Group.

Alcohol Clin Exp Res. 2007 Apr;31(4):555-63.

PMID:
17374034
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk